0	8	Activity	activity	NN
9	11	of	of	IN
12	15	the	the	DT
16	21	kappa	kappa	NN
22	23	B	B	NNP
24	32	enhancer	enhancer	NN
33	35	of	of	IN
36	39	the	the	DT
40	53	interleukin-2	interleukin-2	NN
54	62	receptor	receptor	NN
63	68	alpha	alpha	NN
69	74	chain	chain	NN
75	77	in	in	IN
78	85	somatic	somatic	JJ
86	90	cell	cell	NN
91	98	hybrids	hybrid	NNS
99	101	is	be	VBZ
102	113	accompanied	accompany	VBN
114	116	by	by	IN
117	120	the	the	DT
121	128	nuclear	nuclear	JJ
129	141	localization	localization	NN
142	144	of	of	IN
145	153	NF-kappa	NF-kappa	NNP
154	156	B.	B.	NNP
158	161	The	the	DT
162	165	two	two	CD
166	173	nuclear	nuclear	JJ
174	182	proteins	protein	NNS
183	191	NF-kappa	NF-kappa	NNP
192	193	B	B	NNP
194	195	(	(	(
195	205	consisting	consist	VBG
206	208	of	of	IN
209	217	subunits	subunit	NNS
218	221	p50	p50	NN
222	225	and	and	CC
226	229	p65	p65	NN
229	230	)	)	)
231	234	and	and	CC
235	238	the	the	DT
239	250	DNA-binding	dna-binding	JJ
251	258	subunit	subunit	NN
259	261	of	of	IN
262	270	NF-kappa	NF-kappa	NNP
271	272	B	B	NNP
273	274	(	(	(
274	277	p50	p50	NN
277	278	)	)	)
279	281	by	by	IN
282	288	itself	itself	PRP
288	289	,	,	,
290	294	also	also	RB
295	301	called	call	VBN
302	306	KBF1	kbf1	NN
306	307	,	,	,
308	311	are	be	VBP
312	326	constitutively	constitutively	RB
327	336	expressed	express	VBN
337	340	and	and	CC
341	350	localized	localize	VBN
351	353	in	in	IN
354	357	the	the	DT
358	365	nucleus	nucleus	NN
366	368	of	of	IN
369	372	the	the	DT
373	378	human	human	JJ
379	385	T-cell	t-cell	NN
386	390	line	line	NN
391	395	IARC	IARC	NNP
396	401	301.5	301.5	CD
401	402	.	.	.

403	405	In	in	IN
406	411	order	order	NN
412	414	to	to	TO
415	421	define	define	VB
422	425	the	the	DT
426	431	roles	role	NNS
432	434	of	of	IN
435	440	these	these	DT
441	444	two	two	CD
445	452	factors	factor	NNS
452	453	,	,	,
454	459	which	which	WDT
460	464	bind	bind	VBP
465	467	to	to	TO
468	471	the	the	DT
472	476	same	same	JJ
477	482	kappa	kappa	NN
483	484	B	b	NN
485	494	enhancers	enhancer	NNS
494	495	,	,	,
496	498	in	in	IN
499	512	transcription	transcription	NN
513	523	activation	activation	NN
524	526	we	we	PRP
527	531	have	have	VBP
532	540	prepared	prepare	VBN
541	548	somatic	somatic	JJ
549	553	cell	cell	NN
554	561	hybrids	hybrid	NNS
562	569	between	between	IN
570	574	IARC	IARC	NNP
575	580	301.5	301.5	CD
581	584	and	and	CC
585	586	a	a	DT
587	593	murine	murine	JJ
594	601	myeloma	myeloma	NN
601	602	.	.	.

603	607	Most	most	JJS
608	615	hybrids	hybrid	NNS
616	623	express	express	VBP
624	628	both	both	CC
629	633	KBF1	KBF1	NNP
634	637	and	and	CC
638	646	NF-kappa	NF-kappa	NNP
647	648	B	B	NNP
649	651	in	in	IN
652	657	their	their	PRP$
658	664	nuclei	nucleus	NNS
664	665	,	,	,
666	669	but	but	CC
670	673	one	one	CD
674	680	hybrid	hybrid	NN
681	690	expresses	express	VBZ
691	695	only	only	RB
696	700	KBF1	kbf1	NN
700	701	.	.	.

702	705	The	the	DT
706	711	kappa	kappa	NN
712	713	B	B	NNP
714	722	enhancer	enhancer	NN
723	725	of	of	IN
726	729	the	the	DT
730	734	gene	gene	NN
735	743	encoding	encode	VBG
744	747	the	the	DT
748	761	interleukin-2	interleukin-2	NN
762	763	(	(	(
763	767	IL-2	il-2	NN
767	768	)	)	)
769	777	receptor	receptor	NN
778	783	alpha	alpha	NN
784	789	chain	chain	NN
790	791	(	(	(
791	796	IL-2R	IL-2R	NNP
797	802	alpha	alpha	NN
802	803	)	)	)
804	806	is	be	VBZ
807	817	functional	functional	JJ
818	822	only	only	RB
823	825	in	in	IN
826	829	the	the	DT
830	837	hybrids	hybrid	NNS
838	848	expressing	express	VBG
849	856	nuclear	nuclear	JJ
857	865	NF-kappa	NF-kappa	NNP
866	868	B.	B.	NNP
869	874	These	these	DT
875	883	findings	finding	NNS
884	888	show	show	VBP
889	893	that	that	IN
894	901	nuclear	nuclear	JJ
902	910	NF-kappa	NF-kappa	NNP
911	912	B	B	NNP
913	915	is	be	VBZ
916	925	necessary	necessary	JJ
926	928	to	to	TO
929	937	activate	activate	VB
938	941	the	the	DT
942	947	kappa	kappa	NN
948	949	B	B	NNP
950	958	enhancer	enhancer	NN
958	959	,	,	,
960	965	while	while	IN
966	970	KBF1	kbf1	NN
971	973	by	by	IN
974	980	itself	itself	PRP
981	983	is	be	VBZ
984	987	not	not	RB
988	998	sufficient	sufficient	JJ
998	999	.	.	.

1000	1002	We	we	PRP
1003	1010	propose	propose	VBP
1011	1015	that	that	IN
1016	1020	KBF1	kbf1	NN
1021	1023	is	be	VBZ
1024	1025	a	a	DT
1026	1037	competitive	competitive	JJ
1038	1047	inhibitor	inhibitor	NN
1048	1050	of	of	IN
1051	1059	NF-kappa	NF-kappa	NNP
1060	1061	B	B	NNP
1062	1065	and	and	CC
1066	1073	discuss	discuss	VB
1074	1077	how	how	WRB
1078	1083	these	these	DT
1084	1091	factors	factor	NNS
1092	1095	may	may	MD
1096	1098	be	be	VB
1099	1107	involved	involve	VBN
1108	1110	in	in	IN
1111	1114	the	the	DT
1115	1124	transient	transient	JJ
1125	1135	expression	expression	NN
1136	1138	of	of	IN
1139	1143	IL-2	il-2	NN
1144	1147	and	and	CC
1148	1153	IL-2R	IL-2R	NNP
1154	1159	alpha	alpha	NN
1160	1165	genes	gene	NNS
1166	1172	during	during	IN
1173	1176	the	the	DT
1177	1183	immune	immune	JJ
1184	1192	response	response	NN
1192	1193	.	.	.